COVID Vaccine Authorization Changes Without Advisory Committee Becoming More Common

Decision to allow boosters for 12- to 15-year-old recipients of the Pfizer/BioNTech vaccine will go before CDC's ACIP, but like several other recent changes for COVID vaccines, the US FDA opted to skip its advisory committee.

Vaccine booster
The change in the time between the Pfizer/BioNTech primary series and booster may create more confusion for recipients and providers. • Source: Alamy

In what is becoming a familiar routine, the US Food and Drug Administration expanded the emergency use authorization for the Pfizer Inc./BioNTech SE coronavirus vaccine to allow more groups to receive an additional dose, as well as shortened the time between the primary series and third shot, without an advisory committee meeting.

Children age 12 to 15 now are eligible for a booster shot of the Pfizer/BioNTech vaccine, the FDA announced on 3 January

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Vaccines

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.